Global Beta Blockers Market, By Drugs (Betaxolol, Acebutolol, Esmolol, Atenolol, and Others), Indication (Angina Pectoris, Heart Failure, High Blood Pressure, and Others), End-Users (Hospitals, Homecare, Specialty Clinics, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) – Industry Trends and Forecast to 2030.
Beta Blockers Market Analysis and Size
The demand for the beta blockers market has increased significantly because of advancements in technology, huge investment in R&D, high prevalence and incidence of cardiovascular diseases, and the rising aged population will boost the market growth. Moreover, the increasing patient population and lack of proper treatment will act as an opportunity for market growth. However, post treatment complications and discontinuation of some drugs may hamper the market growth.
Beta blockers are not recommended as a first treatment when you have the most effective excessive blood strain. These are not usually prescribed for high blood pressure until different medications, which include diuretics, must labor effectively. Additionally, health practitioners may prescribe a beta blocker as one of all several medicinal drugs to lower your blood pressure. Beta-blockers may not work as successfully for black and older people, specifically those without different blood strain medications. Beta blockers are used to prevent, deal with or improve symptoms in people with abnormal coronary heart rhythm (arrhythmia), coronary heart failure, Chest ache (angina), coronary heart assaults, migraines, and sure varieties of tremors.
Data Bridge Market Research analyses that the Beta blockers market, which was USD 9,576.09 million in 2023, would rocket up to USD 13,684.08 million by 2030 and is expected to undergo a CAGR of 5.2% during the forecast period.“Incomplete spinal injury” dominates the type segment of the Beta blockers market owing to the increasing number of road accidents. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Beta Blockers Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Drugs (Betaxolol, Acebutolol, Esmolol, Atenolol, and Others), Indication (Angina Pectoris, Heart Failure, High Blood Pressure, and Others), End-Users (Hospitals, Homecare, Specialty Clinics, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, South Africa, rest of Middle East and Africa
|
|
Market Players Covered
|
Pierre Fabre Group (France), ANI Pharmaceuticals, Inc.(U.S.), Mylan N.V. (U.S.), Novartis AG (Switzerland), King Pharma (U.S.), Lupin (India), GlaxoSmithKline plc. (U.K.), Sun Pharmaceutical Industries Ltd.(India), Teva Pharmaceutical Industries Ltd.(Israel), and Amneal Pharmaceuticals LLC. (U.S.) among others.
|
|
Market Opportunities
|
|
Market Definition
The global beta blockers market refers to the market for pharmaceutical drugs known as beta-adrenergic receptor antagonists or beta blockers. It is a class of medications that block the action of adrenaline and other stress hormones on beta receptors in the body. They are primarily used to manage various cardiovascular conditions such as hypertension (high blood pressure), angina (chest pain), arrhythmias (irregular heart rhythms), and heart failure.
Global Beta Blockers Market Dynamics
Drivers
- Increasing Prevalence of Cardiovascular Diseases
The rising incidence of cardiovascular diseases, such as hypertension, angina, and arrhythmias, is a significant driver for the beta blockers market. As these conditions become more prevalent globally, the demand for effective medications such as beta blockers increases.
- Growing Geriatric Population
The aging population is prone to cardiovascular disorders, making them a significant consumer group for beta blockers. With the increasing number of elderly individuals worldwide, there is a higher demand for cardiovascular medications, including beta blockers.
- Increasing Awareness and Diagnosis
Improved cardiovascular health awareness and early diagnosis of related conditions contribute to the demand for beta blockers. With increased health consciousness among individuals and proactive healthcare initiatives, more patients are being diagnosed with cardiovascular diseases, leading to higher prescription rates for beta blockers.
Opportunities
- Advancements in Drug Formulations
Ongoing research and development efforts have led to the development of advanced formulations of beta blockers. These include extended-release formulations that offer a longer duration of action, improved patient compliance, and enhanced therapeutic outcomes. The availability of such innovative formulations acts as an opportunity for market growth.
Restraints/Challenges
- Side Effects and Adverse Reactions
Beta blockers can cause side effects such as fatigue, dizziness, low blood pressure, sexual dysfunction, and depression. These side effects may limit patient adherence to treatment and lead to medication discontinuation. Additionally, some individuals may experience severe adverse reactions, such as bronchospasm in patients with asthma or heart block in certain cardiac conditions, which can restrict the use of beta blockers in specific patient populations.
Recent Development
-
In June 2022, Eagle Pharmaceuticals, Inc. announced that it has submitted the new drug application to U.S. Food and Drug Administration for landiolol, a beta-1 adrenergic blocker, for approval
-
In April 2022, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Camzyos (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules) for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (obstructive HCM) to improve functional capacity and symptoms.
Global Beta Blockers Market Scope
The Beta blockers market is segmented on the basis of drugs, indication, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drugs
- Betaxolol
- Acebutolol
- Esmolol
- Atenolol
- Others
Indication
- Angina Pectoris
- Heart Failure
- High Blood Pressure
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Beta blockers Market Regional Analysis/Insights
The Beta blockers market is analysed and market size insights and trends are provided by country, drugs, indication, end user, and distribution channel as referenced above.
The countries covered in the Beta blockers market report is U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East & Africa.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The Beta blockers market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Beta blockers market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Beta blockers market. The data is available for historic period 2010-2020.
Competitive Landscape and Beta Blockers Market Share Analysis
The Beta blockers market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Beta blockers market.
Some of the major players operating in the Beta blockers market are:
- Pierre Fabre Group (France)
- ANI Pharmaceuticals, Inc. (U.S.)
- Mylan N.V.(U.S.)
- Novartis AG (Switzerland)
- King Pharma (U.S.)
- Lupin (India)
- GlaxoSmithKline plc. (U.K.)
- Sun Pharmaceutical Industries Ltd. (India)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Amneal Pharmaceuticals LLC. (U.S.)
SKU-